Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 3
1950 1
1954 2
1956 1
1964 1
1966 1
1970 1
1971 1
1972 1
1976 1
1987 1
1989 2
1990 1
1991 2
1992 2
1994 1
1995 1
1998 7
1999 3
2000 3
2001 6
2002 1
2004 2
2005 3
2006 3
2007 3
2008 6
2009 6
2010 4
2011 5
2012 7
2013 2
2014 9
2015 5
2016 9
2017 5
2018 7
2019 15
2020 14
2021 18
2022 13
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Gomez E, Gondouin A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Leger J, Kerjouan M, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Bejan-Angoulvant T, Cottin V, Marchand-Adam S; EVER-ILD investigators and the OrphaLung network. Mankikian J, et al. Among authors: prevot g. Eur Respir J. 2023 Jun 8;61(6):2202071. doi: 10.1183/13993003.02071-2022. Print 2023 Jun. Eur Respir J. 2023. PMID: 37230499 Free article. Clinical Trial.
FINDINGS: Between January 2017 and January 2019, 122 randomised patients received at least one dose of rituximab (n=63) or placebo (n=59). The least-squares mean change from baseline to 6 months in FVC (% predicted) was +1.60 (se 1.13) in the rituximab+MMF group and …
FINDINGS: Between January 2017 and January 2019, 122 randomised patients received at least one dose of rituximab (n=63) or placebo ( …
Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process.
Mimouni NEH, Paiva I, Barbotin AL, Timzoura FE, Plassard D, Le Gras S, Ternier G, Pigny P, Catteau-Jonard S, Simon V, Prevot V, Boutillier AL, Giacobini P. Mimouni NEH, et al. Among authors: prevot v. Cell Metab. 2021 Mar 2;33(3):513-530.e8. doi: 10.1016/j.cmet.2021.01.004. Epub 2021 Feb 3. Cell Metab. 2021. PMID: 33539777 Free PMC article.
Hypothalamic bile acid-TGR5 signaling protects from obesity.
Castellanos-Jankiewicz A, Guzmán-Quevedo O, Fénelon VS, Zizzari P, Quarta C, Bellocchio L, Tailleux A, Charton J, Fernandois D, Henricsson M, Piveteau C, Simon V, Allard C, Quemener S, Guinot V, Hennuyer N, Perino A, Duveau A, Maitre M, Leste-Lasserre T, Clark S, Dupuy N, Cannich A, Gonzales D, Deprez B, Mithieux G, Dombrowicz D, Bäckhed F, Prevot V, Marsicano G, Staels B, Schoonjans K, Cota D. Castellanos-Jankiewicz A, et al. Among authors: prevot v. Cell Metab. 2021 Jul 6;33(7):1483-1492.e10. doi: 10.1016/j.cmet.2021.04.009. Epub 2021 Apr 21. Cell Metab. 2021. PMID: 33887197 Free article.
Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells.
Schrijver DP, Röring RJ, Deckers J, de Dreu A, Toner YC, Prevot G, Priem B, Munitz J, Nugraha EG, van Elsas Y, Azzun A, Anbergen T, Groh LA, Becker AMD, Pérez-Medina C, Oosterwijk RS, Novakovic B, Moorlag SJCFM, Jansen A, Pickkers P, Kox M, Beldman TJ, Kluza E, van Leent MMT, Teunissen AJP, van der Meel R, Fayad ZA, Joosten LAB, Fisher EA, Merkx M, Netea MG, Mulder WJM. Schrijver DP, et al. Among authors: prevot g. Nat Biomed Eng. 2023 Sep;7(9):1097-1112. doi: 10.1038/s41551-023-01050-0. Epub 2023 Jun 8. Nat Biomed Eng. 2023. PMID: 37291433 Free PMC article.
Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition.
Priem B, van Leent MMT, Teunissen AJP, Sofias AM, Mourits VP, Willemsen L, Klein ED, Oosterwijk RS, Meerwaldt AE, Munitz J, Prévot G, Vera Verschuur A, Nauta SA, van Leeuwen EM, Fisher EL, de Jong KAM, Zhao Y, Toner YC, Soultanidis G, Calcagno C, Bomans PHH, Friedrich H, Sommerdijk N, Reiner T, Duivenvoorden R, Zupančič E, Di Martino JS, Kluza E, Rashidian M, Ploegh HL, Dijkhuizen RM, Hak S, Pérez-Medina C, Bravo-Cordero JJ, de Winther MPJ, Joosten LAB, van Elsas A, Fayad ZA, Rialdi A, Torre D, Guccione E, Ochando J, Netea MG, Griffioen AW, Mulder WJM. Priem B, et al. Among authors: prevot g. Cell. 2020 Oct 29;183(3):786-801.e19. doi: 10.1016/j.cell.2020.09.059. Cell. 2020. PMID: 33125893 Free PMC article.
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
da Silva Lima N, Fondevila MF, Nóvoa E, Buqué X, Mercado-Gómez M, Gallet S, González-Rellan MJ, Fernandez U, Loyens A, Garcia-Vence M, Chantada-Vazquez MDP, Bravo SB, Marañon P, Senra A, Escudero A, Leiva M, Guallar D, Fidalgo M, Gomes P, Claret M, Sabio G, Varela-Rey M, Delgado TC, Montero-Vallejo R, Ampuero J, López M, Diéguez C, Herrero L, Serra D, Schwaninger M, Prevot V, Gallego-Duran R, Romero-Gomez M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Garcia-Monzon C, Gonzalez-Rodriguez A, Aspichueta P, Nogueiras R. da Silva Lima N, et al. Among authors: prevot v. J Hepatol. 2022 Jan;76(1):11-24. doi: 10.1016/j.jhep.2021.09.008. Epub 2021 Sep 21. J Hepatol. 2022. PMID: 34555423 Free article.
The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. ...
The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases s …
Leptin brain entry via a tanycytic LepR-EGFR shuttle controls lipid metabolism and pancreas function.
Duquenne M, Folgueira C, Bourouh C, Millet M, Silva A, Clasadonte J, Imbernon M, Fernandois D, Martinez-Corral I, Kusumakshi S, Caron E, Rasika S, Deliglia E, Jouy N, Oishi A, Mazzone M, Trinquet E, Tavernier J, Kim YB, Ory S, Jockers R, Schwaninger M, Boehm U, Nogueiras R, Annicotte JS, Gasman S, Dam J, Prévot V. Duquenne M, et al. Among authors: prevot v. Nat Metab. 2021 Aug;3(8):1071-1090. doi: 10.1038/s42255-021-00432-5. Epub 2021 Aug 2. Nat Metab. 2021. PMID: 34341568 Free PMC article.
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.
Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, Chaouat A, Cottin V, De Groote P, Favrolt N, Horeau-Langlard D, Magro P, Savale L, Prévot G, Renard S, Sitbon O, Parent F, Trésorier R, Tromeur C, Piedvache C, Grimaldi L, Fadel E, Montani D, Humbert M, Simonneau G. Jaïs X, et al. Among authors: prevot g. Lancet Respir Med. 2022 Oct;10(10):961-971. doi: 10.1016/S2213-2600(22)00214-4. Epub 2022 Aug 1. Lancet Respir Med. 2022. PMID: 35926542 Clinical Trial.
FINDINGS: Between Jan 19, 2016, and Jan 18, 2019, 105 patients were randomly assigned to riociguat (n=53) or BPA (n=52). At week 26, the geometric mean pulmonary vascular resistance decreased to 39.9% (95% CI 36.2-44.0) of baseline pulmonary vascular resistance in t …
FINDINGS: Between Jan 19, 2016, and Jan 18, 2019, 105 patients were randomly assigned to riociguat (n=53) or BPA (n=52). At we …
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O. Boucly A, et al. Among authors: prevot g. Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC. Am J Respir Crit Care Med. 2021. PMID: 34185620 Free article.
Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with m …
Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual …
Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension.
Guignabert C, Savale L, Boucly A, Thuillet R, Tu L, Ottaviani M, Rhodes CJ, De Groote P, Prévot G, Bergot E, Bourdin A, Howard LS, Fadel E, Beurnier A, Roche A, Jevnikar M, Jaïs X, Montani D, Wilkins MR, Sitbon O, Humbert M. Guignabert C, et al. Among authors: prevot g. Circulation. 2023 Jun 13;147(24):1809-1822. doi: 10.1161/CIRCULATIONAHA.122.061501. Epub 2023 Apr 25. Circulation. 2023. PMID: 37096577
METHODS: Serum levels of activin A, activin B, alpha-subunit of inhibin A and B proteins, and the antagonists follistatin and follistatin-like 3 (FSTL3) were measured in controls and in patients with newly diagnosed idiopathic, heritable, or anorexigen-associated PAH (n=80 …
METHODS: Serum levels of activin A, activin B, alpha-subunit of inhibin A and B proteins, and the antagonists follistatin and follistatin-li …
184 results